Core B: Neuro-Histology and Behavior Core. The overall objective of the Program Project is to study the effects of various gene constructs for treating lysosomal metabolic disorders in mice. If the gene constructs are capable of correcting the metabolic disorders then the treated mice must be studied to determine their phenotype. This will be done histologically to determine if cells express the appropriate enzymes, and whether the pathology has been corrected. Animal phenotype with respect to neurological/behavioral function and auditory neurophysiology will also be evaluated by this core. These services will aid in addressing the central hypothesis ofthe program project, i.e., that gene therapy can correct neurological deficits associated with lysosomal storage disorders. Also, mice that are homozygous for these disorders must be genotyped for proper identification. Core B will provide this genotyping service.

Public Health Relevance

The functions ofthe Neuro-Histology and Behavior Core are integral to the research performed by the Program. This Core provides support for all aspects of animal behavioral assessment, neurohistology, and genotyping for Projects I, II, and III.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Program Projects (P01)
Project #
2P01HD032652-14A2
Application #
8212825
Study Section
Special Emphasis Panel (ZHD1-DSR-Z (WC))
Project Start
Project End
Budget Start
2011-09-20
Budget End
2012-06-30
Support Year
14
Fiscal Year
2011
Total Cost
$173,100
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Ou, Li; Przybilla, Michael J; Whitley, Chester B (2017) Proteomic analysis of mucopolysaccharidosis I mouse brain with two-dimensional polyacrylamide gel electrophoresis. Mol Genet Metab 120:101-110
Ou, Li; Przybilla, Michael J; Koniar, Brenda L et al. (2016) Elements of lentiviral vector design toward gene therapy for treating mucopolysaccharidosis I. Mol Genet Metab Rep 8:87-93
Aronovich, Elena L; Hackett, Perry B (2015) Lysosomal storage disease: gene therapy on both sides of the blood-brain barrier. Mol Genet Metab 114:83-93
Satzer, David; DiBartolomeo, Christina; Ritchie, Michael M et al. (2015) Assessment of dysmyelination with RAFFn MRI: application to murine MPS I. PLoS One 10:e0116788
Wolf, Daniel A; Banerjee, Sharbani; Hackett, Perry B et al. (2015) Gene therapy for neurologic manifestations of mucopolysaccharidoses. Expert Opin Drug Deliv 12:283-96
Hackett, Perry; Carroll, Dana (2015) Regulatory hurdles for agriculture GMOs. Science 347:1324
Ou, Li; Herzog, Tyler L; Wilmot, Carrie M et al. (2014) Standardization of ?-L-iduronidase enzyme assay with Michaelis-Menten kinetics. Mol Genet Metab 111:113-5
Carpentier, Claire E; Schreifels, Jeffrey M; Aronovich, Elena L et al. (2014) NMR structural analysis of Sleeping Beauty transposase binding to DNA. Protein Sci 23:23-33
Hackett, Perry B; Aronovich, Elena L (2014) Rational design for enhanced gene therapy with DNA transposons. Mol Ther 22:1575-7
Janson, Christopher G; Romanova, Liudmila G; Leone, Paola et al. (2014) Comparison of Endovascular and Intraventricular Gene Therapy With Adeno-Associated Virus-?-L-Iduronidase for Hurler Disease. Neurosurgery 74:99-111

Showing the most recent 10 out of 84 publications